Novo Nordisk is actively monitoring and taking action (including but not limited to issuing cease-and-desist letters) against those entities that are engaging in the unlawful sale of compounded semaglutide, disseminating false advertising, and infringing its trademarks. Scott Brunner, CEO of the Alliance for Pharmacy Compounding (A4PC), says that, based on reports from some compounding pharmacies, compounding pharmacies have been able to access semaglutide from legitimate FDA-registered facilities
This distinction matters enormously
And how many other supplements can say that
Take 24 capsules daily in divided doses between meals, as labeled
On Wall Street, Novo Nordisk stock was down 3.6 percent since the market opened
Andersen, N.B., et al., The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats